These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 37904378)

  • 1. Effect of long-acting versus short-acting glucagon-like peptide-1 receptor agonists on improving body weight and related metabolic parameters in type 2 diabetes: A head-to-head meta-analysis.
    Yuan X; Gao Z; Hao Z; Ma H; Duan K; Yang C
    Medicine (Baltimore); 2023 Oct; 102(43):e35739. PubMed ID: 37904378
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and Safety of GLP-1 Receptor Agonists in Patients With Type 2 Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis.
    Zhu Y; Xu J; Zhang D; Mu X; Shi Y; Chen S; Wu Z; Li S
    Front Endocrinol (Lausanne); 2021; 12():769069. PubMed ID: 34956080
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effects of glucagon-like peptide-1 receptor agonists on glycemic control and anthropometric profiles among diabetic patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis of randomized controlled trials.
    Nowrouzi-Sohrabi P; Rezaei S; Jalali M; Ashourpour M; Ahmadipour A; Keshavarz P; Akbari H
    Eur J Pharmacol; 2021 Feb; 893():173823. PubMed ID: 33352183
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparing the effectiveness of long-term use of daily and weekly glucagon-like peptide-1 receptor agonists treatments in patients with nonalcoholic fatty liver disease and type 2 diabetes mellitus: a network meta-analysis.
    Yuan X; Gao Z; Yang C; Duan K; Ren L; Song G
    Front Endocrinol (Lausanne); 2023; 14():1170881. PubMed ID: 37342259
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the Efficacy of Glucagon-Like Peptide-1 Receptor Agonists in Patients With Metabolic Associated Fatty Liver Disease: Updated Systematic Review and Meta-Analysis.
    Dai Y; He H; Li S; Yang L; Wang X; Liu Z; An Z
    Front Endocrinol (Lausanne); 2020; 11():622589. PubMed ID: 33664710
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of glucagon-like peptide-1 receptor agonists on fat accumulation in patients with diabetes mellitus and non-alcoholic fatty liver disease or obesity: A systematic review and meta-analysis of randomized control trials.
    Xie W; Hong Z; Li B; Huang B; Dong S; Cai Y; Ruan L; Xu Q; Mou L; Zhang Y
    J Diabetes Complications; 2024 Jun; 38(6):108743. PubMed ID: 38688179
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of Glucagon-like Peptide-1 Receptor Agonists in Overweight/Obese and/or T2DM Adolescents: A Meta-analysis Based on Randomized Controlled Trials.
    Dai M; Dai S; Gu L; Xiang Z; Xu A; Lu S; Yang Y; Zhou C
    J Clin Res Pediatr Endocrinol; 2024 Sep; 16(3):323-333. PubMed ID: 38828884
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Meta-analysis of head-to-head clinical trials comparing incretin-based glucose-lowering medications and basal insulin: An update including recently developed glucagon-like peptide-1 (GLP-1) receptor agonists and the glucose-dependent insulinotropic polypeptide/GLP-1 receptor co-agonist tirzepatide.
    Nauck MA; Mirna AEA; Quast DR
    Diabetes Obes Metab; 2023 May; 25(5):1361-1371. PubMed ID: 36700380
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists on Body Weight and Cardiometabolic Parameters in Individuals With Obesity and Without Diabetes: A Systematic Review and Meta-Analysis.
    Ansari HUH; Qazi SU; Sajid F; Altaf Z; Ghazanfar S; Naveed N; Ashfaq AS; Siddiqui AH; Iqbal H; Qazi S
    Endocr Pract; 2024 Feb; 30(2):160-171. PubMed ID: 38029929
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis.
    Yao H; Zhang A; Li D; Wu Y; Wang CZ; Wan JY; Yuan CS
    BMJ; 2024 Jan; 384():e076410. PubMed ID: 38286487
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of GLP-1 receptor agonists on the degree of liver fibrosis and CRP in non-alcoholic fatty liver disease and non-alcoholic steatohepatitis: A systematic review and meta-analysis.
    Fang L; Li J; Zeng H; Liu J
    Prim Care Diabetes; 2024 Jun; 18(3):268-276. PubMed ID: 38555202
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of long-acting glucagon-like peptide-1 receptor agonists compared with exenatide twice daily and sitagliptin in type 2 diabetes mellitus: a systematic review and meta-analysis.
    Pinelli NR; Hurren KM
    Ann Pharmacother; 2011 Jul; 45(7-8):850-60. PubMed ID: 21730278
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis.
    Htike ZZ; Zaccardi F; Papamargaritis D; Webb DR; Khunti K; Davies MJ
    Diabetes Obes Metab; 2017 Apr; 19(4):524-536. PubMed ID: 27981757
    [TBL] [Abstract][Full Text] [Related]  

  • 14. GLP-1 Receptor Agonists and Risk of Adverse Cerebrovascular Outcomes in Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Banerjee M; Pal R; Mukhopadhyay S; Nair K
    J Clin Endocrinol Metab; 2023 Jun; 108(7):1806-1812. PubMed ID: 36800286
    [TBL] [Abstract][Full Text] [Related]  

  • 15. First-line treatment with sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists in type 2 diabetic population at low risk of cardiovascular disease: a meta-analysis.
    Deng R; Mei K; Song T; Huang J; Wu Y; Yu P; Yan Z; Liu X
    Front Endocrinol (Lausanne); 2024; 15():1289643. PubMed ID: 38348420
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glucagon-Like Peptide-1 Receptor Agonists for Non-Alcoholic Fatty Liver Disease in Type 2 Diabetes: A Meta-Analysis.
    Wong C; Lee MH; Yaow CYL; Chin YH; Goh XL; Ng CH; Lim AYL; Muthiah MD; Khoo CM
    Front Endocrinol (Lausanne); 2021; 12():609110. PubMed ID: 33897616
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effects of GLP-1 receptor agonists on visceral fat and liver ectopic fat in an adult population with or without diabetes and nonalcoholic fatty liver disease: A systematic review and meta-analysis.
    Liao C; Liang X; Zhang X; Li Y
    PLoS One; 2023; 18(8):e0289616. PubMed ID: 37616255
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment Strategy for Type 2 Diabetes with Obesity: Focus on Glucagon-like Peptide-1 Receptor Agonists.
    Ji Q
    Clin Ther; 2017 Jun; 39(6):1244-1264. PubMed ID: 28526416
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and Safety of Short- and Long-Acting Glucagon-Like Peptide 1 Receptor Agonists on a Background of Basal Insulin in Type 2 Diabetes: A Meta-analysis.
    Huthmacher JA; Meier JJ; Nauck MA
    Diabetes Care; 2020 Sep; 43(9):2303-2312. PubMed ID: 32910778
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of glucagon-like peptide-1 receptor agonists on cardiovascular risk factors: A narrative review of head-to-head comparisons.
    Dalsgaard NB; Vilsbøll T; Knop FK
    Diabetes Obes Metab; 2018 Mar; 20(3):508-519. PubMed ID: 29024408
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.